Cryoport, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Cryoport, Inc. (NASDAQ:CYRX) has received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $12.29.

Several equities research analysts have recently issued reports on CYRX shares. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Friday, January 17th. Guggenheim assumed coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Roth Mkm decreased their price target on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th.

Insider Buying and Selling at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the transaction, the director now directly owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CYRX. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after buying an additional 2,120 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Cryoport in the fourth quarter valued at about $51,000. Avanza Fonder AB bought a new position in shares of Cryoport in the fourth quarter valued at about $64,000. Quarry LP bought a new position in shares of Cryoport in the fourth quarter valued at about $69,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Cryoport in the third quarter valued at about $82,000. 92.90% of the stock is owned by institutional investors.

Cryoport Trading Down 6.2 %

Shares of Cryoport stock opened at $6.22 on Friday. The company’s fifty day simple moving average is $7.64 and its 200-day simple moving average is $7.76. The company has a market cap of $307.45 million, a price-to-earnings ratio of -1.84 and a beta of 1.59. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport has a 1 year low of $5.32 and a 1 year high of $20.10.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.